Public clinical-stage biopharmaceutical and a European pioneer in developing epigenetics-based therapeutics, Oryzon Genomics S.A., recently announced that it has received a €1 million grant to explore new indications for epigenetic inhibitors in combination with other available therapies for the more effective treatment of various tumor types.
This essential public funding (grant: RTC-2017-6407-1), awarded by the Spanish Ministry of Science, Innovation and Universities, and FEDER – European Regional Development Funding allocated by the European Union, has been granted as a 10 year-term reduced interest preferential loan (in multiyear disbursements), will spur the development of these promising anti-cancer agents. The loan will be fully funded in Denmark, Norway, Finland, and Sweden, writes lender Eksperten.
Covering the partial funding of the 3-year project entitled, Evaluation and proof of concept of the effectiveness ORY-1001 in combination therapies in oncological indication (COMBO-EPoC), this investigation, led by Oryzon, is being carried out in collaboration with academic institutions and consortium partners including a trio of centers across Spain: the Health Research Institute Hospital La Fe (ISSLaFe) in Valencia, and Barcelona-based LEITAT Technological Center and the Vall d’Hebron Institute of Oncology (VHIO).
Initiated back in January last year, this inspired undertaking has an aggregated budget of €1.5 million and project partners will each receive up to €0.41 million to carry out their respective research activities aimed at more precisely evaluating the potential of Oryzon’s agents in combination. More specifically, this important funding will further fuel the COMBO-EPoC project in order to establish the therapeutic value of ladademstat (ORY-1001) as well as other epigenetic inhibitors under development.
To discover more about Oryzon Genomics S.A., its therapeutic programs and research collaborations, we invite you to visit: www.oryzon.com.